OBJECTIVE: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. METHODS: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. RESULTS: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. CONCLUSION: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.
OBJECTIVE:Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. METHODS: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. RESULTS:Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. CONCLUSION: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.
Authors: Aleksandra P Vidisheva; James Wang; Tanya M Spektor; Jacob D Bitran; Jose Lutzky; Imad A Tabbara; Joseph Z Ye; Sikander Ailawadhi; Laura V Stampleman; Ronald G Steis; Mehdi M Moezi; Regina A Swift; Tina M Maluso; Kyle A Udd; Shahrooz Eshaghian; Youram Nassir; James R Berenson Journal: Support Care Cancer Date: 2017-04-28 Impact factor: 3.603
Authors: María-Victoria Mateos; Tamas Masszi; Norbert Grzasko; Markus Hansson; Irwindeep Sandhu; Ludek Pour; Luísa Viterbo; Sharon R Jackson; Anne-Marie Stoppa; Peter Gimsing; Mehdi Hamadani; Gabriela Borsaru; Deborah Berg; Jianchang Lin; Alessandra Di Bacco; Helgi van de Velde; Paul G Richardson; Philippe Moreau Journal: Haematologica Date: 2017-07-27 Impact factor: 9.941
Authors: Cyrille Hulin; Javier de la Rubia; Meletios A Dimopoulos; Evangelos Terpos; Eirini Katodritou; Vania Hungria; Hadewijch De Samblanx; Anne-Marie Stoppa; Jesper Aagesen; Deniz Sargin; Anastasia Sioni; Andrew Belch; Joris Diels; Robert A Olie; Don Robinson; Anna Potamianou; Helgi van de Velde; Michel Delforge Journal: Health Sci Rep Date: 2018-12-07